

Rafael Fonseca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5237990/publications.pdf>

Version: 2024-02-01

399
papers

40,144
citations

1463

107
h-index

2747

192
g-index

401
all docs

401
docs citations

401
times ranked

22527
citing authors

#	ARTICLE	IF	CITATIONS
1	Measles, rubella, and mumps titers post chemotherapy plus autologous stem cell transplant in multiple myeloma patients. <i>American Journal of Hematology</i> , 2022, 97, E69.	4.1	1
2	A simple additive staging system for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 21.	6.2	30
3	Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. <i>Lancet Haematology</i> , 2022, 9, e340-e349.	4.6	27
4	Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma. <i>American Journal of Hematology</i> , 2022, , .	4.1	6
5	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	6
6	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. <i>American Journal of Hematology</i> , 2021, 96, E157-E162.	4.1	12
7	Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US. <i>Blood Cancer Journal</i> , 2021, 11, 35.	6.2	1
8	Chromosome 1q21 abnormalities in multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 83.	6.2	64
9	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	3.0	32
10	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 10.	6.2	53
11	Identifying Mechanisms Associated with Venetoclax Resistance in Multiple Myeloma (MM). <i>Blood</i> , 2021, 138, 2668-2668.	1.4	0
12	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , 2021, 138, 1750-1750.	1.4	2
13	Characterization of Atypical t(11;14) CCND1/IGH Translocations in Multiple Myeloma. <i>Blood</i> , 2021, 138, 3771-3771.	1.4	1
14	Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM). <i>Blood</i> , 2021, 138, 2285-2285.	1.4	0
15	Financial Hardship Amongst Patients with Hematologic Malignancies: Using the EMR to Streamline and Prioritize Patient-Centered Care. <i>Blood</i> , 2021, 138, 661-661.	1.4	1
16	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. <i>Blood</i> , 2021, 138, 2650-2650.	1.4	0
17	Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1126-1137.	1.6	161
18	Burden of disease progression in patients with multiple myeloma in the US. <i>Leukemia and Lymphoma</i> , 2020, 61, 47-55.	1.3	16

#	ARTICLE	IF	CITATIONS
19	Targeting TMPRSS2 in SARS-CoV-2 Infection. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1989-1999.	3.0	100
20	Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. <i>BMC Cancer</i> , 2020, 20, 1087.	2.6	42
21	Management of multiple myeloma during COVID-19 pandemic. <i>Leukemia Research Reports</i> , 2020, 14, 100212.	0.4	2
22	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 55.	6.2	36
23	“Direct to Drug” screening as a precision medicine tool in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 54.	6.2	20
24	Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity. <i>Leukemia</i> , 2020, 34, 3060-3063.	7.2	4
25	Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 364-370.	3.8	6
26	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. <i>Nature Cancer</i> , 2020, 1, 493-506.	13.2	209
27	Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma. <i>Value in Health</i> , 2020, 23, 441-450.	0.3	9
28	Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 42-43.	1.4	58
29	Improving the Definition of Response Assessment: Prognostic Value of Minimal Residual Disease Combined with PET/CT at Day 100 Post Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2020, 136, 33-34.	1.4	1
30	Measles, Mumps & Rubella Titers Post Autologous Stem Cell Transplant in Multiple Myeloma Patients Induced with Modern Therapy. <i>Blood</i> , 2020, 136, 43-43.	1.4	0
31	Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monograph. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 9, 1-16.	0.3	0
32	Assessment of MRD in patients with hematologic malignancies: clinical insights. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 9, 7-10.	0.3	0
33	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	2.4	81
34	Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies. <i>Patient Education and Counseling</i> , 2019, 102, 1602-1612.	2.2	24
35	Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 995-1002.	5.2	15
36	Monoclonal antibody utilization characteristics in patients with multiple myeloma. <i>Anti-Cancer Drugs</i> , 2019, 30, 859-865.	1.4	2

#	ARTICLE	IF	CITATIONS
37	High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 239-247.	2.0	27
38	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. <i>Blood</i> , 2019, 134, 1904-1904.	1.4	0
39	Myeloma Cells Addicted to Glutamine for Biomass Production Are Sensitive to Lenalidomide. <i>Blood</i> , 2019, 134, 4410-4410.	1.4	0
40	Approach to a patient with cardiac amyloidosis. <i>Journal of Geriatric Cardiology</i> , 2019, 16, 567-574.	0.2	7
41	Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. <i>Annals of Hematology</i> , 2018, 97, 1453-1462.	1.8	26
42	Diagnosis and Staging of Multiple Myeloma and Related Disorders. <i>Hematologic Malignancies</i> , 2018, , 17-28.	0.2	2
43	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 859-866.	1.6	140
44	Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma. <i>Transplantation</i> , 2018, 102, 1994-2001.	1.0	15
45	The Importance of Economic Trade-offs in Cancer Drug Pricing. <i>Mayo Clinic Proceedings</i> , 2018, 93, 976-979.	3.0	4
46	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 70.	6.2	18
47	Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 486-492.e1.	0.4	7
48	Characterization of Frontline Treatment Patterns and Attrition Rates According to Subsequent Lines of Therapy in Non-Transplant Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 3291-3291.	1.4	2
49	Results of a Flow Cytometry Assay Measuring Oxidative Stress Relief As a Predictor of Immunomodulatory Drugs (IMiDs) Sensitivity in Myeloma. <i>Blood</i> , 2018, 132, 4443-4443.	1.4	0
50	Hereditary Lysozyme Amyloidosis Variant p.Leu102Ser Associates with Unique Phenotype. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 431-438.	6.1	27
51	Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e727-e734.	1.9	3
52	A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR ϵ CD) for untreated low ϵ grade non ϵ Hodgkin lymphoma requiring therapy. <i>American Journal of Hematology</i> , 2017, 92, 467-472.	4.1	15
53	Antibodies Create Killer Bonds in Myeloma. <i>Cancer Cell</i> , 2017, 31, 305-307.	16.8	2
54	Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2017, 92, 578-598.	3.0	115

#	ARTICLE	IF	CITATIONS
55	Multiple myeloma cells' capacity to decompose H ₂ O ₂ determines lenalidomide sensitivity. <i>Blood</i> , 2017, 129, 991-1007.	1.4	33
56	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	7.1	110
57	Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, 642.	6.2	15
58	Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 621-630.	0.4	5
59	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 555-562.	0.4	28
60	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017, 130, 1198-1204.	1.4	54
61	Prevalence of BCL-2/(H) Translocation in Healthy African Americans. <i>Annals of Hematology</i> , 2017, 96, 51-55.	1.8	1
62	Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics. <i>Blood</i> , 2017, 130, 864-864.	1.4	4
63	Erdheim Chester Disease treated successfully with cladribine. <i>Respiratory Medicine Case Reports</i> , 2016, 18, 37-40.	0.4	12
64	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	1.4	110
65	Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2016, 91, E504-E505.	4.1	6
66	IAP antagonists induce anti-tumor immunity in multiple myeloma. <i>Nature Medicine</i> , 2016, 22, 1411-1420.	30.7	133
67	Extramedullary Cardiac Multiple Myeloma—A Case Report and Contemporary Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 246-252.	0.4	16
68	Bone Disease in Myeloma: The Claws of CRAB. <i>Clinical Cancer Research</i> , 2016, 22, 1301-1303.	7.0	1
69	Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. <i>Blood</i> , 2016, 128, 491-491.	1.4	21
70	PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation. <i>Oncotarget</i> , 2016, 7, 61806-61819.	1.8	23
71	Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. <i>Blood</i> , 2015, 125, 443-448.	1.4	195
72	Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 125, 492-498.	1.4	47

#	ARTICLE	IF	CITATIONS
73	Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. <i>Blood</i> , 2015, 126, 1294-1301.	1.4	80
74	Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. <i>Clinical Cancer Research</i> , 2015, 21, 3986-3994.	7.0	172
75	Treatment of Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1054-1081.	3.0	106
76	Targeted sequencing using a 47 gene multiple myeloma mutation panel (M ³ P) in 17p high risk disease. <i>British Journal of Haematology</i> , 2015, 168, 507-510.	2.5	42
77	Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements. <i>PLoS ONE</i> , 2014, 9, e87113.	2.5	14
78	Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma. <i>PLoS Genetics</i> , 2014, 10, e1004135.	3.5	292
79	IMWG consensus on risk stratification in multiple myeloma. <i>Leukemia</i> , 2014, 28, 269-277.	7.2	500
80	Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. <i>Blood</i> , 2014, 124, 536-545.	1.4	190
81	Activity of 129 Single-Agent Drugs in 228 Phase I and II Clinical Trials in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 284-290.e5.	0.4	15
82	Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. <i>Leukemia</i> , 2014, 28, 1725-1735.	7.2	221
83	Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. <i>Cancer Cell</i> , 2014, 25, 91-101.	16.8	847
84	Staging and prognostication of multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 21-31.	2.2	33
85	Amitriptyline-Induced Agranulocytosis With Bone Marrow Confirmation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e183-e185.	0.4	1
86	Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. <i>Thrombosis Research</i> , 2014, 133, 606-609.	1.7	14
87	Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2014, 167, 563-565.	2.5	41
88	The clinical significance of cereblon expression in multiple myeloma. <i>Leukemia Research</i> , 2014, 38, 23-28.	0.8	84
89	Molecular Classification and Risk Stratification. , 2014, , 55-64.		0
90	Dissecting Karyotypic Patterns in Non-Hyperdiploid Multiple Myeloma: An Overview on the Karyotypic Evolution. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 552-558.	0.4	5

#	ARTICLE	IF	CITATIONS
91	Smoldering multiple myeloma requiring treatment: time for a new definition?. <i>Blood</i> , 2013, 122, 4172-4181.	1.4	70
92	Myeloma: Classification and Risk Assessment. <i>Seminars in Oncology</i> , 2013, 40, 554-566.	2.2	24
93	Genomic Abnormalities of Waldenström Macroglobulinemia and Related Low-Grade B-Cell Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 198-201.	0.4	18
94	Recurrent Chromosome Abnormalities Define Nonoverlapping Unique Subgroups of Tumors in Patients With Chronic Lymphocytic Leukemia and Known Karyotypic Abnormalities. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 467-476.	0.4	3
95	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. <i>Mayo Clinic Proceedings</i> , 2013, 88, 360-376.	3.0	440
96	CGH Protocols: Chronic Lymphocytic Leukemia. <i>Methods in Molecular Biology</i> , 2013, 973, 87-98.	0.9	3
97	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. <i>Leukemia</i> , 2013, 27, 780-791.	7.2	294
98	Cytogenetic Abnormalities in MGUS and Myeloma. , 2013, , 589-599.		0
99	Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. <i>Leukemia</i> , 2013, 27, 925-931.	7.2	31
100	Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. <i>Leukemia</i> , 2013, 27, 711-717.	7.2	174
101	Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. <i>Leukemia</i> , 2013, 27, 1738-1744.	7.2	194
102	Lessons from next-generation sequencing analysis in hematological malignancies. <i>Blood Cancer Journal</i> , 2013, 3, e127-e127.	6.2	50
103	The MYDas touch of next-gen sequencing. <i>Blood</i> , 2013, 121, 2373-2374.	1.4	8
104	Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. <i>Blood</i> , 2013, 121, 3147-3152.	1.4	53
105	Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. <i>Haematologica</i> , 2013, 98, 1586-1592.	3.5	50
106	A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma. <i>PLoS ONE</i> , 2013, 8, e66361.	2.5	41
107	Phase II Trial Of Initial Safety and Toxicity Prior To The Phase III Trial Of Lenalidomide Versus Observation Alone In Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated By The Eastern Cooperative Oncology Group. <i>Blood</i> , 2013, 122, 3174-3174.	1.4	2
108	The Genomic Landscape Of Primary Central Nervous System Lymphomas. <i>Blood</i> , 2013, 122, 504-504.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Genomic Strategies Determining Progression from MGUS to Multiple Myeloma. , 2013, , 3-24.		0
110	Genetics of Multiple Myeloma. , 2013, , 1-16.		0
111	Intracellular Accumulation Of Light Chains Caused By Lenalidomide, and Mediated Via CRBN, Causes Major ER Stress and Is Implicated In The Synergistic Combination Of Imids and Proteasome Inhibitors. Blood, 2013, 122, 4434-4434.	1.4	0
112	Genomic Landscape and Clonal Heterogeneity Underlying Progression and Relapse In Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 2855-2855.	1.4	0
113	High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler). Blood, 2013, 122, 1854-1854.	1.4	0
114	Calcium Isotopic Composition and Its Association With Multiple Myeloma Disease Activity. Blood, 2013, 122, 3157-3157.	1.4	0
115	Role Of Folate Receptor Targeted Therapy In Multiple Myeloma. Blood, 2013, 122, 4436-4436.	1.4	0
116	How Physicians Interpret Research Funding Disclosures. New England Journal of Medicine, 2012, 367, 2358-2360.	27.0	3
117	Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma. Leukemia, 2012, 26, 1671-1674.	7.2	11
118	Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood, 2012, 119, 5397-5404.	1.4	144
119	Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. Modern Pathology, 2012, 25, 651-660.	5.5	66
120	Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood, 2012, 120, 2280-2289.	1.4	208
121	Thrombosis in multiple myeloma (MM). Hematology, 2012, 17, s177-s180.	1.5	40
122	Frontline treatment of multiple myeloma. Hematology, 2012, 17, s101-s104.	1.5	3
123	t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. Blood, 2012, 120, 3949-3957.	1.4	48
124	Cyclophosphamide-bortezomib-dexamethasone (CyBORd) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood, 2012, 119, 4391-4394.	1.4	338
125	Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood, 2012, 120, 1060-1066.	1.4	357
126	Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood, 2012, 119, 4860-4867.	1.4	119

#	ARTICLE	IF	CITATIONS
127	Molecular pathogenesis of Waldenstrom's macroglobulinemia. <i>Haematologica</i> , 2012, 97, 1281-1290.	3.5	35
128	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. <i>Blood</i> , 2012, 119, 2100-2105.	1.4	218
129	Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. <i>Leukemia</i> , 2012, 26, 1698-1701.	7.2	46
130	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	7.2	664
131	Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing. <i>PLoS ONE</i> , 2012, 7, e43192.	2.5	62
132	Association of Clinical Researchers and Educators A Statement on Relationships Between Physicians and Industry. <i>Endocrine Practice</i> , 2012, 18, 1029-1037.	2.1	3
133	Clonal competition with alternating dominance in multiple myeloma. <i>Blood</i> , 2012, 120, 1067-1076.	1.4	575
134	A Pilot Program in Collaboration with African American Churches Successfully Increases Awareness of the Importance of Cancer Research and Participation in Cancer Translational Research Studies among African Americans. <i>Journal of Cancer Education</i> , 2012, 27, 294-298.	1.3	6
135	A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2012, 156, 326-333.	2.5	48
136	Content Development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): Use of Qualitative and Quantitative Methods for Scale Construction. <i>Journal of Pain and Symptom Management</i> , 2012, 43, 1094-1104.	1.2	45
137	Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma. <i>Blood</i> , 2012, 120, 194-194.	1.4	11
138	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicting Outcome in 345 Patients. <i>Blood</i> , 2012, 120, 201-201.	1.4	16
139	Phase II Trial of Initial Safety and Toxicity Prior to the Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated by the Eastern Cooperative Oncology Group. <i>Blood</i> , 2012, 120, 4079-4079.	1.4	1
140	Genome-Wide Analysis Uncovers Recurrent Alterations in Primary Central Nervous System Lymphomas. <i>Blood</i> , 2012, 120, 420-420.	1.4	1
141	An Integrated Genomic and Expression Analysis of 7q Deletion in Splenic Marginal Zone Lymphoma. <i>PLoS ONE</i> , 2012, 7, e44997.	2.5	53
142	DNA Methylation in Multiple Myeloma Is Weakly Associated with Gene Transcription. <i>PLoS ONE</i> , 2012, 7, e52626.	2.5	20
143	PARP Inhibition (OLAPARIB) Enhance Melphalan and Nutlin-3a Sensitivity in TP53 Positive Multiple Myeloma. <i>Blood</i> , 2012, 120, 1846-1846.	1.4	1
144	Promiscuous Cryptic Rearrangements of the MYC Locus Cis-Dysregulate MYC Expression and Are Present in the Majority of Patients with Hyperdiploid Myeloma. <i>Blood</i> , 2012, 120, 724-724.	1.4	1

#	ARTICLE	IF	CITATIONS
145	DNA Methylation in Multiple Myeloma Is Weakly Associated with Gene Transcription. <i>Blood</i> , 2012, 120, 1285-1285.	1.4	0
146	The Role of the Histone Demethyltransferase Gene JMJD1C and H3K9 Methylation in Multiple Myeloma. <i>Blood</i> , 2012, 120, 3527-3527.	1.4	1
147	Tissue Factor and Hematological Neoplasias. <i>Blood</i> , 2012, 120, 5132-5132.	1.4	0
148	Unraveling the multiple myeloma genome in the next-generation sequencing era: challenges to translating knowledge into the clinic. <i>Expert Review of Hematology</i> , 2011, 4, 579-581.	2.2	1
149	High-Throughput Genomic Analysis in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 106-108.	0.4	19
150	Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. <i>Leukemia</i> , 2011, 25, 1026-1035.	7.2	239
151	Monoclonal Gammopathy of Undetermined Significance Does Not Affect Outcomes in Patients Undergoing Solid Organ Transplants. <i>Transplantation</i> , 2011, 92, 570-574.	1.0	32
152	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. <i>Blood</i> , 2011, 117, 4696-4700.	1.4	285
153	Establishment and characterization of a novel Waldenström macroglobulinemia cell line, MWCL-1. <i>Blood</i> , 2011, 117, e190-e197.	1.4	40
154	Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. <i>Blood</i> , 2011, 118, 4359-4362.	1.4	39
155	Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. <i>Blood</i> , 2011, 118, 2970-2975.	1.4	193
156	Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. <i>Blood</i> , 2011, 118, 4771-4779.	1.4	552
157	Innovation in myeloma treatments PARP excellence!. <i>Blood</i> , 2011, 118, 6234-6235.	1.4	2
158	Impact of high-risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03. <i>British Journal of Haematology</i> , 2011, 155, 340-348.	2.5	29
159	Initial genome sequencing and analysis of multiple myeloma. <i>Nature</i> , 2011, 471, 467-472.	27.8	1,288
160	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. <i>American Journal of Hematology</i> , 2011, 86, 640-645.	4.1	57
161	Plasma cell leukemia. <i>Blood Reviews</i> , 2011, 25, 107-112.	5.7	81
162	MicroRNA expression in tumor cells from Waldenström's macroglobulinemia reflects both their normal and malignant cell counterparts. <i>Blood Cancer Journal</i> , 2011, 1, e24-e24.	6.2	18

#	ARTICLE	IF	CITATIONS
163	Primary Central Nervous System Lymphomas: A Validation Study of Array-Based Comparative Genomic Hybridization in Formalin-Fixed Paraffin-Embedded Tumor Specimens. <i>Clinical Cancer Research</i> , 2011, 17, 4245-4253.	7.0	52
164	A Novel Measure of Chromosome Instability Is An Independent Prognostic Factor in Multiple Myeloma. <i>Blood</i> , 2011, 118, 1824-1824.	1.4	1
165	Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. <i>Blood</i> , 2011, 118, 2942-2942.	1.4	2
166	Variation in Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients by Insurance Coverage. <i>Blood</i> , 2011, 118, 3150-3150.	1.4	1
167	Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,. <i>Blood</i> , 2011, 118, 3963-3963.	1.4	4
168	Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,. <i>Blood</i> , 2011, 118, 4184-4184.	1.4	5
169	Association of Race with Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients. <i>Blood</i> , 2011, 118, 5070-5070.	1.4	1
170	Longitudinal Genome Wide Analysis of Patients with Chronic Lymphocytic Leukemia Reveals Complex Evolution of Clonal Architecture At Disease Progression and At the Time of Relapse. <i>Blood</i> , 2011, 118, 2838-2838.	1.4	0
171	Generation of An Automated Tool for the Identification of Genetics Markers and Signatures in Multiple Myeloma Risk-Stratification. <i>Blood</i> , 2011, 118, 2881-2881.	1.4	0
172	Comprehensive High-Resolution Studies Differentiate and Characterize Hypodiploid Multiple Myeloma. <i>Blood</i> , 2011, 118, 2869-2869.	1.4	0
173	Comparison of Cytogenetics Between Asian and Caucasian Myeloma Reveal Higher Frequency of Abnormalities Associated with Poor Prognosis in Asian Patients. <i>Blood</i> , 2011, 118, 5060-5060.	1.4	0
174	Cereblon Expression Is Required for the Anti-Myeloma Activity of Lenalidomide and Pomalidomide. <i>Blood</i> , 2011, 118, 127-127.	1.4	0
175	Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. <i>Blood</i> , 2010, 115, 1343-1350.	1.4	119
176	Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. <i>Blood</i> , 2010, 115, 1594-1604.	1.4	95
177	Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. <i>Blood</i> , 2010, 115, 3416-3417.	1.4	179
178	Clarithromycin (Biaxin)â€lowâ€dose dexamethasone (BiRd) versus lenalidomideâ€lowâ€dose dexamethasone (Rd) for newly diagnosed myeloma. <i>American Journal of Hematology</i> , 2010, 85, 664-669.	4.1	49
179	Monoclonal gammopathy of undetermined significance: a consensus statement. <i>British Journal of Haematology</i> , 2010, 150, 28-38.	2.5	95
180	Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. <i>Leukemia</i> , 2010, 24, 1498-1505.	7.2	34

#	ARTICLE	IF	CITATIONS
181	Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. <i>Leukemia</i> , 2010, 24, 1406-1411.	7.2	44
182	Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). <i>Leukemia</i> , 2010, 24, 1934-1939.	7.2	182
183	Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. <i>Leukemia</i> , 2010, 24, 833-842.	7.2	41
184	DNA Methylation Analysis Determines the High Frequency of Genic Hypomethylation and Low Frequency of Hypermethylation Events in Plasma Cell Tumors. <i>Cancer Research</i> , 2010, 70, 6934-6944.	0.9	61
185	Evidence for Cytogenetic and Fluorescence In Situ Hybridization Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. <i>Mayo Clinic Proceedings</i> , 2010, 85, 532-537.	3.0	55
186	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications. <i>Mayo Clinic Proceedings</i> , 2010, 85, 197-199.	3.0	5
187	Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. <i>Cancer Genetics and Cytogenetics</i> , 2010, 203, 161-168.	1.0	35
188	Treatment With Bortezomib of a Patient Having Hyper IgG4 Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 217-219.	0.4	62
189	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines. <i>Mayo Clinic Proceedings</i> , 2010, 85, 824-833.	3.0	152
190	Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. <i>Lancet</i> , The, 2010, 375, 1721-1728.	13.7	313
191	Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. <i>Lancet Oncology</i> , The, 2010, 11, 29-37.	10.7	882
192	La genética como factor pronóstico y terapéutico en el mieloma múltiple. <i>Revista Medica De Chile</i> , 2009, 137, .	0.2	1
193	Spontaneous Remission in a Patient With t(4;14) Translocation Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2009, 27, e194-e197.	1.6	4
194	Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor- κ B Signaling Pathways in Waldenström's Macroglobulinemia. <i>Cancer Research</i> , 2009, 69, 3579-3588.	0.9	154
195	Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5008-5014.	1.6	286
196	Centrosomes and myeloma; Aneuploidy and proliferation. <i>Environmental and Molecular Mutagenesis</i> , 2009, 50, 697-707.	2.2	14
197	International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. <i>Leukemia</i> , 2009, 23, 2210-2221.	7.2	775
198	Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. <i>Leukemia</i> , 2009, 23, 1337-1341.	7.2	347

#	ARTICLE	IF	CITATIONS
199	High-Resolution Genomic Analysis in Waldenström's Macroglobulinemia Identifies Disease-Specific and Common Abnormalities with Marginal Zone Lymphomas. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 39-42.	1.4	32
200	Pomalidomide (CC4047) plus Low-Dose Dexamethasone (Pom/Dex) as Therapy for Relapsed Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S46-S47.	1.4	1
201	Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. <i>Mayo Clinic Proceedings</i> , 2009, 84, 1095-1110.	3.0	389
202	Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications. <i>Blood</i> , 2009, 113, 635-645.	1.4	52
203	Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. <i>Blood</i> , 2009, 114, 518-521.	1.4	130
204	Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. <i>Haematologica</i> , 2009, 94, 380-386.	3.5	94
205	Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2009, 114, 2868-2868.	1.4	3
206	Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients.. <i>Blood</i> , 2009, 114, 2877-2877.	1.4	0
207	Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2009, 114, 3884-3884.	1.4	0
208	MYC Activation Is a Common Transformation Event in Myeloma and Associated with Poor Prognosis.. <i>Blood</i> , 2009, 114, 834-834.	1.4	0
209	CpG Methylation Profiling in Multiple Myeloma.. <i>Blood</i> , 2009, 114, 604-604.	1.4	0
210	Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDAC) alone (95-80-53) or 2-CDAC and rituximab (N0189) in the North Central Cancer Treatment Group. <i>Cancer</i> , 2008, 113, 108-116.	4.1	68
211	A novel report of ciga-FISH and cytogenetics in POEMS syndrome. <i>American Journal of Hematology</i> , 2008, 83, 840-841.	4.1	17
212	Clinical and biological significance of RAS mutations in multiple myeloma. <i>Leukemia</i> , 2008, 22, 2280-2284.	7.2	150
213	Genetic aberrations and survival in plasma cell leukemia. <i>Leukemia</i> , 2008, 22, 1044-1052.	7.2	299
214	Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. <i>Leukemia</i> , 2008, 22, 459-461.	7.2	31
215	Do β_2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy?. <i>Leukemia</i> , 2008, 22, 1080-1081.	7.2	3
216	Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. <i>Leukemia</i> , 2008, 22, 1282-1284.	7.2	118

#	ARTICLE	IF	CITATIONS
217	Cell lines of hyperdiploid myeloma, are we there yet?. British Journal of Haematology, 2008, 140, 579-580.	2.5	2
218	AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies. Cancer Cell, 2008, 13, 167-180.	16.8	322
219	Consolidation Therapy with Bortezomib/Lenalidomide/Dexamethasone Versus Bortezomib/Dexamethasone After a Dexamethasone-Based Induction Regimen in Patients with Multiple Myeloma: A Randomized Phase III Trial. Clinical Lymphoma and Myeloma, 2008, 8, 315-317.	1.4	12
220	Comparison of Twin and Autologous Transplants for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2008, 14, 1118-1124.	2.0	28
221	Effect of Tissue Shipping on Plasma Cell Isolation, Viability, and RNA Integrity in the Context of a Centralized Good Laboratory Practiceâ€“Certified Tissue Banking Facility. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 666-673.	2.5	17
222	Phase I, Pharmacokinetic and Pharmacodynamic Study of the Antiâ€“Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma. Journal of Clinical Oncology, 2008, 26, 3196-3203.	1.6	152
223	Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10â€“%549 patients from the International Myeloma Working Group. Blood, 2008, 111, 4039-4047.	1.4	190
224	The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood, 2008, 111, 1603-1609.	1.4	111
225	Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood, 2008, 111, 785-789.	1.4	355
226	Biologic and genetic characterization of the novel amyloidogenic lambda light chainâ€“secreting human cell lines, ALMC-1 and ALMC-2. Blood, 2008, 112, 1931-1941.	1.4	64
227	Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. Journal of Clinical Investigation, 2008, 118, 1750-64.	8.2	52
228	Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease.. Blood, 2008, 112, 1663-1663.	1.4	1
229	Effect of Venous Thrombotic Events on Overall Survival in Multiple Myeloma: Analysis of Thrombotic Events Occurring in E4A03A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma, a Trial Coordinated by the Eastern Cooperative Oncology Group (ECOG).. Blood, 2008, 112, 1740-1740.	1.4	5
230	Phase II Trial of Lenalidomide (Revlimidâ„¢) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma. Blood, 2008, 112, 91-91.	1.4	8
231	Cytogenetic Abnormalities in Multiple Myeloma: The Importance of FISH and Cytogenetics. , 2008, , 57-76.		0
232	Association of High Levels of Free Light Chain and the Presence of Igh Translocations in Multiple Myeloma and Prognostic Implications.. Blood, 2008, 112, 1677-1677.	1.4	0
233	Proteomic Analysis of Multiple Myeloma Identifies Upregulation of CR1K Protein, a Novel Protein Regulating Migration and Adhesion. Blood, 2008, 112, 643-643.	1.4	0
234	Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling. Cancer Research, 2007, 67, 2982-2989.	0.9	236

#	ARTICLE	IF	CITATIONS
235	Strategies for Risk-Adapted Therapy in Myeloma. Hematology American Society of Hematology Education Program, 2007, 2007, 304-310.	2.5	11
236	Proteomic Analysis of Waldenstrom Macroglobulinemia. Cancer Research, 2007, 67, 3777-3784.	0.9	56
237	Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach. Molecular Cancer Therapeutics, 2007, 6, 802-810.	4.1	24
238	Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood, 2007, 109, 1228-1232.	1.4	78
239	Multiple myeloma and FISH (but no CHIPS). Blood, 2007, 109, 3132-3133.	1.4	1
240	Genomics and proteomics in multiple myeloma and Waldenström macroglobulinemia. Current Opinion in Hematology, 2007, 14, 369-374.	2.5	8
241	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. Mayo Clinic Proceedings, 2007, 82, 323-341.	3.0	143
242	Transfusion-Dependent Anemia After Initiation of Androgen Deprivation Therapy for Metastatic Prostate Cancer. Urology, 2007, 70, 811.e5-811.e8.	1.0	5
243	Prognostic Factors and Staging in Multiple Myeloma. Hematology/Oncology Clinics of North America, 2007, 21, 1115-1140.	2.2	40
244	Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. New England Journal of Medicine, 2007, 356, 2582-2590.	27.0	740
245	Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma. Mayo Clinic Proceedings, 2007, 82, 1179-1184.	3.0	142
246	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. Mayo Clinic Proceedings, 2007, 82, 323-341.	3.0	155
247	Review of molecular diagnostics in multiple myeloma. Expert Review of Molecular Diagnostics, 2007, 7, 453-459.	3.1	16
248	A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia, 2007, 21, 529-534.	7.2	191
249	Clinical significance of TP53 mutation in myeloma. Leukemia, 2007, 21, 582-584.	7.2	140
250	Expression and mutation status of candidate kinases in multiple myeloma. Leukemia, 2007, 21, 1124-1127.	7.2	15
251	Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. Leukemia, 2007, 21, 2358-2359.	7.2	18
252	Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia, 2007, 21, 2035-2042.	7.2	317

#	ARTICLE	IF	CITATIONS
253	6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. <i>British Journal of Haematology</i> , 2007, 136, 80-86.	2.5	109
254	Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2007, 138, 700-720.	2.5	109
255	Promiscuous Mutations Activate the Noncanonical NF- κ B Pathway in Multiple Myeloma. <i>Cancer Cell</i> , 2007, 12, 131-144.	16.8	941
256	Phase 1 Dose Escalation Study of the Monoclonal Antibody Against the Insulin Like Growth Factor I Receptor CP-751,871 in Patients with Multiple Myeloma.. <i>Blood</i> , 2007, 110, 1171-1171.	1.4	2
257	Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma.. <i>Blood</i> , 2007, 110, 190-190.	1.4	7
258	Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).. <i>Blood</i> , 2007, 110, 241-241.	1.4	1
259	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. <i>Blood</i> , 2007, 110, 2477-2477.	1.4	1
260	A Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls.. <i>Blood</i> , 2007, 110, 3601-3601.	1.4	4
261	A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.. <i>Blood</i> , 2007, 110, 74-74.	1.4	57
262	Genomic-Wide Profiling of Gene Expression and DNA Copy Number Alterations in Multiple Myeloma.. <i>Blood</i> , 2007, 110, 396-396.	1.4	0
263	Multiple Myeloma (MM) Is Characterized by Genomic Instability Regardless of Ploidy Categories and Degree of Karyotypic Complexity Is an Important Prognostic Factor.. <i>Blood</i> , 2007, 110, 1476-1476.	1.4	0
264	Dissecting Karyotypic Patterns in Non Hyperdiploid Multiple Myeloma: An Overview on the Karyotypic Evolution.. <i>Blood</i> , 2007, 110, 2491-2491.	1.4	0
265	Waldenström Macroglobulinaemia: The Impact of Cytogenetic Analysis.. <i>Blood</i> , 2007, 110, 2490-2490.	1.4	0
266	The Multiple Myeloma Research Consortium Genomics Initiative.. <i>Blood</i> , 2007, 110, 2498-2498.	1.4	0
267	Identification of Survival Critical Genomic Gains or Losses in Myeloma (MM) Using Array-Comparative Genomic Hybridization (aCGH).. <i>Blood</i> , 2007, 110, 2471-2471.	1.4	0
268	Gene Expression Profiling of Pulmonary Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Identifies New Diagnostic Markers, Biological Heterogeneity and Therapeutic Targets.. <i>Blood</i> , 2007, 110, 560-560.	1.4	1
269	Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2006, 81, 1047-1053.	3.0	221
270	Clinical implication of centrosome amplification in plasma cell neoplasm. <i>Blood</i> , 2006, 107, 3669-3675.	1.4	90

#	ARTICLE	IF	CITATIONS
271	Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. <i>Blood</i> , 2006, 108, 2755-2763.	1.4	166
272	Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. <i>British Journal of Haematology</i> , 2006, 133, 158-164.	2.5	128
273	IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma. <i>Leukemia</i> , 2006, 20, 174-176.	7.2	55
274	Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. <i>Leukemia</i> , 2006, 20, 807-813.	7.2	129
275	Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. <i>Leukemia</i> , 2006, 20, 2034-2040.	7.2	195
276	Ploidy status rarely changes in myeloma patients at disease progression. <i>Leukemia Research</i> , 2006, 30, 266-271.	0.8	31
277	6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. <i>Cancer Genetics and Cytogenetics</i> , 2006, 169, 150-153.	1.0	105
278	Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 1111-1120.	2.8	37
279	A phase II trial of imatinib in patients with refractory/relapsed myeloma. <i>Leukemia and Lymphoma</i> , 2006, 47, 39-42.	1.3	43
280	Natural history of thromboembolism in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2006, 13, 31-36.	3.0	28
281	Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 431-436.	1.6	802
282	High Incidence of IgH Translocations in Monoclonal Gammopathies with Abnormal Free Light Chain Levels.. <i>Blood</i> , 2006, 108, 3514-3514.	1.4	6
283	Single Agent Bortezomib Is Associated with a High Response Rate in Patients with High Risk Myeloma. A Phase II Study from the Eastern Cooperative Oncology Group (E2A02).. <i>Blood</i> , 2006, 108, 3527-3527.	1.4	9
284	Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival.. <i>Blood</i> , 2006, 108, 798-798.	1.4	31
285	A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.. <i>Blood</i> , 2006, 108, 799-799.	1.4	48
286	High Density Oligonucleotide Array CGH Analysis of CLL Reveals Areas of Recurrent Genomic Gain or Loss.. <i>Blood</i> , 2006, 108, 2093-2093.	1.4	0
287	High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3407-3407.	1.4	0
288	Establishment and Characterization of an Ig Lambda Secreting Cell Line from a Patient with AL Amyloidosis.. <i>Blood</i> , 2006, 108, 3520-3520.	1.4	7

#	ARTICLE	IF	CITATIONS
289	Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. Blood, 2006, 108, 3587-3587.	1.4	0
290	Combined High Resolution Array Comparative Genomic Hybridization and Gene Expression Profiling Reveal Rb1 Haploinsufficiency as a Possible Tumorigenic Mechanism in Myeloma.. Blood, 2006, 108, 113-113.	1.4	1
291	Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood, 2005, 105, 794-803.	1.4	52
292	A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood, 2005, 106, 2156-2161.	1.4	115
293	Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood, 2005, 106, 2837-2840.	1.4	337
294	Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood, 2005, 106, 3553-3558.	1.4	117
295	A "not so micro" model for a "macro" problem. Blood, 2005, 106, 1143-1144.	1.4	1
296	Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 2005, 106, 4050-4053.	1.4	604
297	A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia, 2005, 19, 118-125.	7.2	46
298	Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell, 2005, 7, 39-49.	16.8	202
299	Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem cell transplantation and review of the literature. American Journal of Hematology, 2005, 78, 288-294.	4.1	71
300	Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling. Journal of Clinical Oncology, 2005, 23, 6339-6344.	1.6	123
301	Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance. Journal of Clinical Oncology, 2005, 23, 5668-5674.	1.6	110
302	Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma. Journal of Clinical Oncology, 2005, 23, 5347-5356.	1.6	509
303	Genomics in multiple myeloma: biology and clinical implications. Pharmacogenomics, 2005, 6, 563-573.	1.3	10
304	Risk Stratification of Patients with Newly Diagnosed Multiple Myeloma: Optimizing Treatment Based on Pretreatment Characteristics. Clinical Lymphoma and Myeloma, 2005, 6, 200-207.	1.4	6
305	Genetics of multiple myeloma. Best Practice and Research in Clinical Haematology, 2005, 18, 525-536.	1.7	13
306	A Phase II Study of PS-341 for Patients with High Risk, Newly Diagnosed Multiple Myeloma: A Trial of the Eastern Cooperative Oncology Group (E2A02).. Blood, 2005, 106, 2546-2546.	1.4	4

#	ARTICLE	IF	CITATIONS
307	Use of the Serum Free Light Chain Assay in Assessment of Response to Therapy in Multiple Myeloma: Validation of Recently Proposed Response Criteria in a Prospective Clinical Trial of Lenalidomide Plus Dexamethasone for Newly Diagnosed Multiple Myeloma.. Blood, 2005, 106, 3479-3479.	1.4	2
308	Gene Expression Profiling of Myeloma Cells at Diagnosis Can Predict Response to Therapy with Thalidomide and Dexamethasone Combination.. Blood, 2005, 106, 508-508.	1.4	2
309	Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.. Blood, 2005, 106, 781-781.	1.4	5
310	Clinical Significance of the Tumor Suppressor p53 Codon 72 Polymorphic Variants in Multiple Myeloma.. Blood, 2005, 106, 5102-5102.	1.4	0
311	Myeloma with t(11;14) and CD20+ Plasma Cells: Response to Rituximab.. Blood, 2005, 106, 5178-5178.	1.4	0
312	Identification of Genes Associated with Increased Bone Marrow Angiogenesis in Multiple Myeloma.. Blood, 2005, 106, 5109-5109.	1.4	0
313	Comparison of Newly Diagnosed and Relapsed Refractory Multiple Myeloma Using Transcriptional Profiling of Myeloma Cells.. Blood, 2005, 106, 1555-1555.	1.4	0
314	Plasma Cells from Secondary Plasma Cell Leukemia Display Different Cytogenetics Pattern When Compared with Primary Plasma Cell Leukemia.. Blood, 2005, 106, 3267-3267.	1.4	0
315	Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis. Journal of Clinical Oncology, 2004, 22, 3751-3757.	1.6	774
316	Genetics and Cytogenetics of Multiple Myeloma. Cancer Research, 2004, 64, 1546-1558.	0.9	642
317	High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplantation, 2004, 34, 161-167.	2.4	82
318	Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplantation, 2004, 34, 235-239.	2.4	62
319	Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplantation, 2004, 34, 485-490.	2.4	52
320	Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia, 2004, 18, 624-627.	7.2	88
321	Analysis of Somatic Hypermutation and Antigenic Selection in the Clonal B Cell in Immunoglobulin Light Chain Amyloidosis (AL). Journal of Clinical Immunology, 2004, 24, 340-353.	3.8	24
322	Initial immunoglobulin M ?flare? after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia. Cancer, 2004, 101, 2593-2598.	4.1	190
323	Clinical Course of Patients With Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2004, 79, 867-874.	3.0	319
324	Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood, 2004, 103, 1799-1806.	1.4	127

#	ARTICLE	IF	CITATIONS
325	Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. <i>Blood</i> , 2004, 104, 1881-1887.	1.4	300
326	Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. <i>Blood</i> , 2004, 103, 3271-3277.	1.4	163
327	Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. <i>Blood</i> , 2004, 104, 40-42.	1.4	128
328	Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. <i>Blood</i> , 2004, 103, 3960-3963.	1.4	226
329	Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group.. <i>Blood</i> , 2004, 104, 129-129.	1.4	6
330	Combination Therapy with CC-5013 (Lenalidomide; Revlimid [®]) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).. <i>Blood</i> , 2004, 104, 331-331.	1.4	16
331	Waldenström Macroglobulinemia. , 2004, , 205-225.		0
332	Plasma Cell Folate Receptor Overexpression Differentiates Multiple Myeloma from Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma.. <i>Blood</i> , 2004, 104, 3649-3649.	1.4	2
333	Clinical Implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32) and -17p13 (p53) Deletions in Myeloma Patients Treated with High Dose Therapy.. <i>Blood</i> , 2004, 104, 334-334.	1.4	1
334	Associations of DNA Repair Gene Polymorphisms in XRCC1 and ERCC2 with Clinical Outcome in ECOG Trial E9486.. <i>Blood</i> , 2004, 104, 1475-1475.	1.4	0
335	Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy.. <i>Blood</i> , 2004, 104, 2446-2446.	1.4	0
336	Proteomic Analysis of Targeted Therapeutic Agents in Multiple Myeloma (MM).. <i>Blood</i> , 2004, 104, 4299-4299.	1.4	0
337	Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) Identifies Potential Targets for Drug Therapy.. <i>Blood</i> , 2004, 104, 787-787.	1.4	0
338	The Lack of Clinical Efficacy of Flavopiridol in Patients with Relapsed Refractory Myeloma.. <i>Blood</i> , 2004, 104, 3461-3461.	1.4	0
339	Deletion 13 by FISH Provides Prognostic Information on Overall Survival and Time to Progression Independent of Serum Beta 2 Microglobulin and Bone Marrow Plasma Cell Labeling Index in Myeloma Patients Undergoing Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 4852-4852.	1.4	0
340	Sequencing the Multiple Myeloma Kinome: Absence of Mutation in Known Malignancy-Associated Kinases.. <i>Blood</i> , 2004, 104, 783-783.	1.4	0
341	Genetics and cytogenetics of Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 142-145.	2.2	27
342	Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 110-115.	2.2	841

#	ARTICLE	IF	CITATIONS
343	t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients. British Journal of Haematology, 2003, 120, 170-171.	2.5	14
344	Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. British Journal of Haematology, 2003, 123, 305-308.	2.5	31
345	Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia, 2003, 17, 427-436.	7.2	208
346	Thalidomide as initial therapy for early-stage myeloma. Leukemia, 2003, 17, 775-779.	7.2	219
347	Expression of VEGF and its receptors by myeloma cells. Leukemia, 2003, 17, 2025-2031.	7.2	140
348	Many and multiple myeloma(s). Leukemia, 2003, 17, 1943-1944.	7.2	25
349	Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2003, 78, 34-39.	3.0	122
350	Waldenström macroglobulinaemia. Lancet Oncology, The, 2003, 4, 679-685.	10.7	138
351	Review of 1027 Patients With Newly Diagnosed Multiple Myeloma. Mayo Clinic Proceedings, 2003, 78, 21-33.	3.0	1,904
352	POEMS syndrome: definitions and long-term outcome. Blood, 2003, 101, 2496-2506.	1.4	694
353	Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood, 2003, 101, 4569-4575.	1.4	599
354	Assays for Neoplastic Cell Enrichment in Bone Marrow Samples. , 2003, 85, 333-342.		1
355	Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 257-261.	3.0	126
356	Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood, 2003, 101, 827-830.	1.4	69
357	Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood, 2003, 101, 1715-1717.	1.4	105
358	Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood, 2003, 101, 3801-3807.	1.4	207
359	The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood, 2003, 102, 2562-2567.	1.4	257
360	Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma. Journal of Clinical Oncology, 2002, 20, 4319-4323.	1.6	479

#	ARTICLE	IF	CITATIONS
361	Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. <i>Blood</i> , 2002, 100, 2996-3001.	1.4	199
362	Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. <i>Blood</i> , 2002, 99, 3735-3741.	1.4	308
363	Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. <i>Blood</i> , 2002, 99, 2627-2627.	1.4	107
364	Genomic abnormalities in monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2002, 100, 1417-1424.	1.4	317
365	Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression. <i>Cancer Genetics and Cytogenetics</i> , 2002, 132, 55-60.	1.0	55
366	Bone marrow angiogenesis in multiple myeloma: effect of therapy. <i>British Journal of Haematology</i> , 2002, 119, 665-671.	2.5	48
367	Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. <i>Cancer Research</i> , 2002, 62, 715-20.	0.9	150
368	Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. <i>Clinical Cancer Research</i> , 2002, 8, 2210-6.	7.0	219
369	Genomic abnormalities in monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2002, 100, 1417-24.	1.4	117
370	Eligibility for Hematopoietic Stem-Cell Transplantation for Primary Systemic Amyloidosis Is a Favorable Prognostic Factor for Survival. <i>Journal of Clinical Oncology</i> , 2001, 19, 3350-3356.	1.6	154
371	The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2001, 98, 1271-1272.	1.4	89
372	Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. <i>Blood</i> , 2001, 98, 2266-2268.	1.4	135
373	Plasma cell leukemia. <i>Current Treatment Options in Oncology</i> , 2001, 2, 205-216.	3.0	36
374	Detection of diagnostically critical, often hidden, anomalies in complex karyotypes of haematological disorders using multicolour fluorescence in situ hybridization. <i>British Journal of Haematology</i> , 2001, 112, 975-980.	2.5	27
375	Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2001, 68, 269-275.	4.1	61
376	Laboratory correlates in multiple myeloma: how useful for prognosis?. <i>Blood Reviews</i> , 2001, 15, 97-102.	5.7	8
377	Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. <i>Leukemia</i> , 2001, 15, 981-986.	7.2	123
378	Thalidomide for previously untreated indolent or smoldering multiple myeloma. <i>Leukemia</i> , 2001, 15, 1274-1276.	7.2	151

#	ARTICLE	IF	CITATIONS
379	Testicular lymphoma is associated with a high incidence of extranodal recurrence. <i>Cancer</i> , 2000, 88, 154-161.	4.1	147
380	Author reply. <i>Cancer</i> , 2000, 89, 714-714.	4.1	2
381	Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. <i>British Journal of Haematology</i> , 2000, 109, 24-29.	2.5	65
382	The (11;14)(q13;q32) Translocation in Multiple Myeloma. <i>American Journal of Clinical Pathology</i> , 2000, 113, 831-837.	0.7	111
383	FISH Demonstrates Treatment-Related Chromosome Damage in Myeloid but not Plasma Cells in Primary Systemic Amyloidosis. <i>Leukemia and Lymphoma</i> , 2000, 39, 391-395.	1.3	11
384	Waldenström's Macroglobulinemia. <i>Oncologist</i> , 2000, 5, 63-67.	3.7	104
385	Thalidomide in the Treatment of Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2000, 75, 897-901.	3.0	173
386	Plasmablastic Morphology Is an Independent Predictor of Poor Survival After Autologous Stem-Cell Transplantation for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 1999, 17, 1551-1551.	1.6	64
387	Clinical Significance of the Translocation (11;14)(q13;q32) in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1999, 35, 599-605.	1.3	31
388	Cytogenetic Abnormalities Correlate with the Plasma Cell Labeling Index and Extent of Bone Marrow Involvement in Myeloma. <i>Cancer Genetics and Cytogenetics</i> , 1999, 113, 73-77.	1.0	91
389	CYTOGENETIC ABNORMALITIES IN MULTIPLE MYELOMA. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 1169-1180.	2.2	22
390	Cerebral Toxicity in Patients Treated for Small Cell Carcinoma of the Lung. <i>Mayo Clinic Proceedings</i> , 1999, 74, 461-465.	3.0	49
391	Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: A review. <i>American Journal of Hematology</i> , 1998, 59, 161-167.	4.1	169
392	Anemia After Orchiectomy. <i>American Journal of Hematology</i> , 1998, 59, 230-233.	4.1	62
393	Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. <i>British Journal of Haematology</i> , 1998, 101, 296-301.	2.5	70
394	Chromosomal abnormalities in systemic amyloidosis. <i>British Journal of Haematology</i> , 1998, 103, 704-710.	2.5	49
395	The Case of the Phantom Bladder. <i>Journal of Urology</i> , 1997, 157, 1354-1354.	0.4	2
396	Follicular dendritic cell sarcoma mimicking diffuse large cell lymphoma: A case report. , 1997, 55, 148-155.		34

#	ARTICLE	IF	CITATIONS
397	Practical Aspects in the Diagnosis and Management of Aplastic Anemia. American Journal of the Medical Sciences, 1997, 313, 159-169.	1.1	11
398	DIAGNOSIS AND GENETIC CLASSIFICATION OF MULTIPLE MYELOMA. , 0, , 1-17.		1
399	Plasma cell neoplasms. , 0, , 244-265.		0